## CORRESPONDENCE

side effects, contraindications, and risks vs. benefits of its use for approved medical conditions.

Medical cannabis is seen as a legitimate medical therapy by many Missouri physicians and is here to stay. Labeling physicians who advocate medical cannabis as "unethical" is a disservice to reputable Missouri physicians and to current MSMA members who see a benefit of medical cannabis use in their patients. The MSMA should be an inclusive organization and embrace scientific cannabis education for its members and readers of *Missouri Medicine*. *Marc K. Taormina, MD, FACP, FACG, FASGE, AGAF* 

MSMA Member since 1979 Midwest GI Health Lee's Summit, Missouri

## **Cannabis and Pregnancy Don't Mix**

In the September/October 2020 *Missouri Medicine*, Polocaro and Vettraino raise the important issue of the transgenerational effects of prenatal cannabinoid exposure (PCE) on subsequent generations.<sup>1</sup> The implications of multigenerational toxicity of cannabinoids is very far-reaching with major policy implications.

The picture presented by Polcaro and Vettraino relating to the mental health implications of PCE is correct if too conservative. As they observe the subject is deeply confounded with multiple other factors impacting post-natal neurological development. For these reasons the significant concordance between reports from five longitudinal studies of childhood development relating to impaired indices of concentration, startle, excitability, poor visuospatial processing and executive functioning including ADHD-like and autism-like features are of particular concern.<sup>2-6</sup> Under a legalization paradigm the state effectively condones unlimited all day every day exposure to extremely high concentrations of THC, other cannabinoids and cannabis tars. What is especially concerning about this is that many of the neurotoxic and neurodevelopmental toxicities of cannabis exhibit threshold dose effects above which severe damage becomes commonplace.<sup>7</sup> In the context of an increasingly solid consensus relating to the harmful impacts of adult and adolescent cannabis exposure<sup>8</sup> the implications of PCE-neurotoxicity have not been carefully considered. It has been shown that

nationwide autism rates are undergoing an exponential rise and indeed New Jersey has been shown to have 4.5% of 8-year-old boys who carry an autism spectrum disorder diagnosis.<sup>9,10</sup> Our space-time and causal inference studies demonstrate that indeed cannabinoid exposure to THC and cannabigerol amongst other fractions of cannabis, is a principal driver of this nationwide epidemic (manuscript submitted).<sup>9,10</sup>

A very concerning consensus is now emerging relating to cannabis-induced teratogenesis, embryotoxicity and fetotoxicity. A 2007 Hawaiian study found that 21 birth defects including many cardiovascular defects, Downs syndrome, orofacial clefts, gastroschisis and arm and hand defects were elevated in offspring of women exposed only to cannabis gestationally with odds ratios up to 40-fold and upper confidence intervals to 123-fold.<sup>11</sup> A report on Canada found that total congenital defects were three times more common in the northern territories where cannabis is smoked about three times as much.<sup>12,13</sup> In October 2018 Colorado Health reported an excess of 20,152 total birth defects beyond their baseline expected 67,620 defects 2000-2013 across the period of cannabis legalization when the use of other drugs was falling, representing an elevation of 29.8% above background rates.<sup>14</sup> In a high cannabis use area of Australia 13 defects were found to be elevated compared to Queensland, which for methodological reasons is a conservative estimate.<sup>15</sup> Concerningly elevated rates of Downs syndrome in Colorado, Hawaii, Australia and Canada clearly indicate that heritable cannabis genotoxicity can occur at the hundred megabase chromosomal scale.<sup>11,12,14,15</sup> A close association of atrial septal defect (secundum type) with rising patterns of cannabis use across space and time in the US was recently reported, suggesting that the list of known teratological associations of prenatal cannabis exposure is as yet incomplete.<sup>16</sup> This epidemiological literature is closely concordant with studies in experimental animals.<sup>17-19</sup> Again an abrupt rise in genotoxicity with increasing cannabinoid exposure has been demonstrated for many cannabinoids and is of particular concern.<sup>20-23</sup>

Links between cannabis and several paediatric cancers including acute lymphoid leukaemia (ALL), acute myeloid leukaemia, rhabdomyosarcoma and neuroblastoma suggest further implications of cannabinoid genotoxicity.<sup>24-28</sup> Since these tumours together encompass the common tumours of childhood, it is at least possible that cannabis is responsible for the 43% elevation in total childhood cancer across US 1975-2017.<sup>29</sup> Indeed Downs syndrome is well known to be associated with a 2,000-fold elevated risk of childhood ALL from 2/100,000 to around 5/100.<sup>30,31</sup>

This diverse assemblage of highly congruent evidence of severe cannabis-related neurotoxicity and genotoxicity from varied locations can only be described as extremely concerning indeed. In view of its well described epigenetic and chromoanagenetic effects<sup>32-34</sup> and its clearly transgenerationalmultigenerational impacts one can only conclude that if the evidence base is not admitted to the cannabis debate and access to fetotoxic and embryotoxic cannabinoids is not immediately restricted the community will inevitably pay a heinous price in terms of avoidable paediatric neurotoxicity, congenital birth defects, heritable cancerogenesis and multigenerational epigenotoxicity.

> Albert Stuart Reece, MD, MBBS, FRCS, FRACGP Gary Kenneth Hulse, PhD, BBSc MBSc Division of Psychiatry, University of Western Australia, Crawley, Western Australia & School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia

## References

1. Polocaro J., Vettraino I.M. Cannabis in Pregnancy and Lactation - A Review. Missouri Medicine. 2020;117:400-405.

 Brents L. Correlates and consequences of Prenatal Cannabis Exposure (PCE): Identifying and Characterizing Vulnerable Maternal Populations and Determining Outcomes in Exposed Offspring In: Preedy V.R., ed. Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis and Treatment. Vol 1. London: Academic Press; 2017:160-170.
 Smith AM, Mioduszewski O, Hatchard T, Byron-Alhassan A, Fall C, Fried PA. Prenatal marijuana exposure impacts executive functioning into young adulthood: An fMRI study. Neurotoxicol Teratol. 2016;58:53-59.
 Smith AM, Longo CA, Fried PA, Hogan MJ, Cameron I. Effects of marijuana on visuospatial working memory: an fMRI study in young adults. Psychopharmacology (Berl). 2010;210(3):429-438.
 Paul SE, Hatoum AS, Fine JD, et al. Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study. JAMA Psychiatry. 2020. p e202902 doi: 10.1001/jamapsychiatry.2020.2902

G. Fine JD, Moreau AL, Karcher NR, et al. Association of Prenatal Cannabis Exposure With Psychosis Proneness Among Children in the Adolescent Brain Cognitive Development (ABCD) Study. JAMA Psychiatry. 2019;76(7):762-764.
7. Spencer S, Neuhofer D, Chioma VC, et al. A Model of Delta(9)-

Tetrahydrocannabinol Self-administration and Reinstatement That Alters Synaptic Plasticity in Nucleus Accumbens. Biol Psychiatry. 2018;84(8):601-610. 8. Reece AS, Hulse GK. Co-occurrence across time and space of drug- and cannabinoid- exposure and adverse mental health outcomes in the National Survey of Drug Use and Health: combined geotemporospatial and causal inference analysis. BMC Public Health. 2020;20(1):1655.

9. Reece A.S., Hulse G.K. Effect of Cannabis Legalization on US Autism Incidence and Medium Term Projections. Clinical Pediatrics: Open Access. 2019;4(2):1-17.

10. Reece A. S., Hulse G.K. Epidemiological Associations of Various Substances and Multiple Cannabinoids with Autism in USA. Clinical Pediatrics: Open Access. 2019;4(2):1-20.

11. Forrester MB, Merz RD. Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002. Journal of toxicology and environmental health. 2007;70(1):7-18.

12. Reece AS, Hulse GK. Canadian Cannabis Consumption and Patterns of Congenital Anomalies: An Ecological Geospatial Analysis. J Addict Med. 2020; 14 (5), e195-e210.

13. Reece A. S., Hulse G.K. Cannabis Consumption Patterns Parallel the East-West Gradient in Canadian Neural Tube Defect Incidence: An Ecological Study. Global Pediatric Health. 2019; 6:1222794X19894798..

 Reece AS, Hulse GK. Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends. Clin Pediatr (Phila). 2019;58(10):1085-1123.
 Reece A.S., Hulse G.K. Broad Spectrum Epidemiological Contribution of Cannabis and Other Substances to the Teratological Profile of Northern New South Wales: Geospatial and Causal Inference Analysis BMC Pharmacology and Toxicology. 2020; 21 (1): 75-102.

 Reece A. S., Hulse G.K. Contemporary Epidemiology of Rising Atrial Septal Defect Trends Across USA 1991-2016: A Combined Ecological Geospatiotemporal and Causal Inferential Study. BMC Pediatrics. 2020;In Press.
 Graham JDP, Cannabis and Health. In: Graham JDP, ed. Cannabis and Health. Vol 1. 1 ed. London, New York, San Francisco: Academic Press; 1976:271-320.

 Geber WF, Schramm LC. Effect of marihuana extract on fetal hamsters and rabbits. Toxicology and applied pharmacology. 1969;14(2):276-282.
 Geber WF, Schramm LC. Teratogenicity of marihuana extract as

influenced by plant origin and seasonal variation. Arch Int Pharmacodyn Ther. 1969;177(1):224-230.

20. Shoyama Y, Sugawa C, Tanaka H, Morimoto S. Cannabinoids act as necrosis-inducing factors in Cannabis sativa. Plant Signal Behav. 2008;3(12):1111-1112.

21. Fisar Z, Singh N, Hroudova J. Cannabinoid-induced changes in respiration of brain mitochondria. Toxicology letters. 2014;231(1):62-71.

22. Singh N, Hroudova J, Fisar Z. Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria. J Mol Neurosci. 2015;56(4):926-931.

23. Russo C, Ferk F, Misik M, et al. Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells. Archives of toxicology. 2019; 93 (1) 179-188.

24. Kuijten RR, Bunin GR, Nass CC, Meadows AT. Gestational and familial risk factors for childhood astrocytoma: results of a case-control study. Cancer Res. 1990;50(9):2608-2612.

25. Robison LL, Buckley JD, Daigle AE, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group). Cancer. 1989;63(10):1904-1911.

26. Trivers KF, Mertens AC, Ross JA, et al. Parental marijuana use and risk of childhood acute myeloid leukaemia: a report from the Children's Cancer Group (United States and Canada). Paediatric and perinatal epidemiology. 2006;20(2):110-118.

27. Grufferman S, Schwartz AG, Ruymann FB, Maurer HM. Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control. 1993;4(3):217-224.

 Wen WQ, Shu XO, Steinbuch M, et al. Paternal military service and risk for childhood leukemia in offspring. Am J Epidemiol. 2000;151(3):231-240.
 National Cancer Institute SEAERSP. SEER Explorer. National Cancer Institute, Surveillance Epidemiology and End Results (SEER) Program,. https:// seer.cancer.gov/explorer/application.html. Published 2020. Accessed August 6th, 2020, 2020.

30. Birger Y, Shiloh R, Izraeli S. Mechanisms of Leukemia Evolution: Lessons from a Congenital Syndrome. Cancer Cell. 2019;36(2):115-117.

31. Labuhn M, Perkins K, Matzk S, et al. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell. 2019;36(2):123-138 e110.

32. Recee AS, Hulse GK. Chromothripsis and epigenomics complete causality criteria for cannabis- and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity. Mutat Res. 2016;789:15-25.

33. Reece AS, Hulse GK. Impacts of Cannabinoid Epigenetics on Human Development: Reflections on Murphy et. al. 'Cannabinoid Exposure and Altered DNA Methylation in Rat and Human Sperm' Epigenetics 2018; 13: 1208-1221. Epigenetics. 2019:1-16.

34. Reece AS, Wang W, Hulse GK. Pathways from epigenomics and glycobiology towards novel biomarkers of addiction and its radical cure. Medical hypotheses. 2018;116:10-21.